Nine Chapters Capital Management’s ProQR Therapeutics PRQR Stock Holding History

Nine Chapters Capital Management’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	$133K	Buy	+27,400	New	+$142K	0.29%	114

Other funds holding PRQR

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AGA

Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Nine Chapters Capital Management's PRQR Position: Q3 2017 in Review

Nine Chapters Capital Management opened a new position in ProQR Therapeutics (PRQR) in Q3 2017: 27,400 shares worth $133K. The stake represents 0.29% of the portfolio and ranks #114 among its holdings.

23 funds tracked by Wall St. Rank hold PRQR as of Q3 2017.

Nine Chapters Capital Management held 27,400 shares of ProQR Therapeutics worth $133K as of Q3 2017.
ProQR Therapeutics was a new Nine Chapters Capital Management position in Q3 2017.
ProQR Therapeutics made up 0.29% of Nine Chapters Capital Management's portfolio in Q3 2017, its #114 holding.
23 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q3 2017.

Based on Nine Chapters Capital Management's 13F filing for Q3 2017, filed 31 Oct 2017.